Analyst Research

Report Title Price
Provider: S&P Capital IQ Quantitative Report
Provider: Reuters Investment Profile
Provider: ValuEngine, Inc.
Provider: Wright Reports

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Urologix Inc Reaffirms FY 2013 Revenue Guidance

Wednesday, 1 May 2013 04:00pm EDT 

Urologix Inc reaffirmed fiscal 2013 revenue guidance range of approximately $16.0-$17.0 million. According to I/B/E/S Estimates, analysts on an average were expecting the Company to report revenues of $16.4 million for fiscal 2013. 

Company Quote

0.0020 +2.47%
27 Feb 2015